NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.
Read Original Story

Special Report: Life and death in the age of the bionic heart

Rating

2 Star

Special Report: Life and death in the age of the bionic heart

Our Review Summary

 This is a story about some of the new medical devices either on the market or in development to help people with serious heart conditions live longer.  The story included several personal vignettes of individuals whose lives have been markedly improved with the technology.   The story did a good job providing an interesting description of technology, but it failed to included any quantitative information that readers could use for insight about the likelihood of benefit or of harm from the use of the devices.

 

Why This Matters

It is not possible for readers to evaluate the value of a treatment in the absence of information about how well devices work, how often problems occur, and how much treatment costs.  So, while we applaud the space and time provided to report on this topic, we think that some of the space and time should have been given over to an exploration of some of the issues we look for in our criteria. 

Criteria

Does the story adequately discuss the costs of the intervention?

Not Satisfactory

 There was no discussion of costs – a huge issue.  We learn a portfolio manager’s projection of the size of the potential market, but not a word about costs to the individual or to society.

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

 The three patients interviewed had clear improvement in their quality of life.  The story provided no data to assess how representative their experience was.

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

 The story mentioned that infections, bleeding and stroke are fairly common without explaining what "common" really means.  Are these problems that occur in more than half of patients? 25% 10% or ?%.

The story also raised the issue of what to do when the implanted device is able to keep pumping even though the patient’s other organ systems have shut down.  But it provided no insight about how often this issue was something families of patients have to deal with.

Does the story seem to grasp the quality of the evidence?

Not Satisfactory

 The story included human interest vignettes rather than evidence.   The story said that one of the manufacturers cited 1-2 year survival data of 60-70%, but we weren’t told if this is published and, if so, where.  That’s not a rigorous evaluation of the evidence.

Does the story commit disease-mongering?

Not Satisfactory

There is no disease-mongering of end-stage cardiovascular disease.  But there is in another area.  The story raised the specter of ‘unnatural death’, a potential issue that can come up for patients who have the implanted device.  It quoted a clinical ethicist saying, "It’s not hard to imagine a person who has had severe stroke that has impacted both sides of the brain, the kidneys are shutting down, he is on a respirator, but yet the LVAD just keeps churning along." But stories should do more than "imagine" – they should report on true track records.  The story didn’t give readers an idea of how frequently this is an issue.

Does the story use independent sources and identify conflicts of interest?

Satisfactory

 Several clinicians and patients were interviewed as part of this story.

Does the story compare the new approach with existing alternatives?

Not Satisfactory

 The story did not compare outcomes of patients following different treatment approaches. 

Does the story establish the availability of the treatment/test/product/procedure?

Satisfactory

 It was clear from this story that the HeartMate II is an available product though the story did not indicate whether implantation of the device was something that could be done at any hospital or only in specialty facilities.  

Does the story establish the true novelty of the approach?

Satisfactory

 The story was pretty clear that the LVAD and TETS technology had been around. 

Does the story appear to rely solely or largely on a news release?

Satisfactory

Given the depth of the story, it’s clear that it didn’t rely solely or largely on a news release.

Total Score: 4 of 10 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.